(2-溴-5-氟苯基)肼盐酸盐 | 60481-35-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (2-溴-5-氟苯基)肼盐酸盐
• 英文名称: (2-bromo-5-fluoro-phenyl)-hydrazine hydrochloride
• 英文别名: 1-(2-bromo-5-fluorophenyl)hydrazine hydrochloride；(2-Bromo-5-fluorophenyl)hydrazine hydrochloride；(2-bromo-5-fluorophenyl)hydrazine;hydrochloride
• CAS: 60481-35-8
• 化学式: C₆H₆BrFN₂*ClH
• 分子量: 241.49
• InChiKey: FIZCDIBJUUNWCD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  38
• 氢给体数：
  3
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C

反应信息

• 作为反应物：
  描述：

  (2-溴-5-氟苯基)肼盐酸盐 在 硫酸 、 (Bis(tri-tert-butylphosphine)palladium⁽⁰⁾) 、 水 、 potassium carbonate 、 caesium carbonate 、 二异丙胺 、 sodium hydroxide 作用下， 以 乙二醇二甲醚 、 乙醇 、 正己烷 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 43.5h， 生成 4,4’-[4-fluoro-7-(2-{4-[4-(3-fluoro-2-methylphenyl)butoxy]phenyl}ethynyl)-2-methyl-1H-indole-1,3-diyl]dibutanoic acid
  参考文献：
  名称：

  Discovery of Gemilukast (ONO-6950), a Dual CysLT₁ and CysLT₂ Antagonist As a Therapeutic Agent for Asthma

  摘要：

  An orally active dual CysLT(1) and CysLT(2) antagonist possessing a distinctive structure which consists of triple bond and dicarboxylic acid moieties is described. Gemilukast (ONO-6950) was generated via isomerization of the core indole and the incorporation of a triple bond into a lead compound. Gemilukast exhibited antagonist activities with IC50 values of 1.7 and 25 nM against human CysLT(1) and human CysLT(2), respectively, and potent efficacy at an oral dose of 0.1 mg/kg given 24 h before LTD4 challenge in a CysLT(1)-dependent guinea pig asthmatic model. In addition, gemilukast dose-dependently reduced LTC4-induced bronchoconstriction in both CysLT(1)- and CysLT(2)-dependent guinea pig asthmatic models, and it reduced antigen-induced constriction of isolated human bronchi. Gemilukast is currently being evaluated in phase II trials for the treatment of asthma.

  DOI：

  10.1021/acs.jmedchem.5b00741
• 作为产物：
  描述：

  2-溴-5-氟苯胺 生成 (2-溴-5-氟苯基)肼盐酸盐
  参考文献：
  名称：

  HIV integrase inhibitors

  摘要：

  这项发明涵盖了一系列公式I的双环嘧啶酮化合物，它们能抑制HIV整合酶，防止病毒整合到人类DNA中。这一作用使得这些化合物对治疗HIV感染和艾滋病具有用处。该发明还涵盖了用于治疗HIV感染者的药物组合物和方法。

  公开号：

  US20070111984A1

文献信息

• Substituted tetrahydro-1H-pyrido[4,3-b]indoles as serotonin receptors agonists and antagonists
  申请人：Lee Taekyu

  公开号：US20070027178A1

  公开（公告）日：2007-02-01

  The present application describes compounds, including all pharmaceutically acceptable salts, prodrugs, solvates and stereoisomers thereof, according to Formula I, pharmaceutical compositions, comprising at least one compound according to Formula I and optionally at least one additional therapeutic agent and methods of treating various diseases, conditions and disorders associated with modulation of serotonin receptors such as, for example: metabolic diseases, which includes but is not limited to obesity, diabetes, diabetic complications, atherosclerosis, impared glucose tolerance and dyslipidemia; central nervous system diseases which includes but is not limited to, anxiety, depression, obsessive compulsive disorder, panic disorder, psychosis, schizophrenia, sleep disorder, sexual disorder and social phobias; cephalic pain; migraine; and gastrointestinal disorders using compounds according to Formula I

  本申请描述了化合物，包括所有药用盐、前药、溶剂合物和其立体异构体，根据式I，包括至少一种根据式I的化合物的药物组合物，以及可选择地至少一种额外的治疗剂，以及使用根据式I的化合物治疗与调节5-羟色胺受体相关的各种疾病、状况和紊乱的方法，例如：代谢性疾病，包括但不限于肥胖症、糖尿病、糖尿病并发症、动脉粥样硬化、葡萄糖耐量受损和血脂异常；中枢神经系统疾病，包括但不限于焦虑症、抑郁症、强迫症、惊恐症、精神病、精神分裂症、睡眠障碍、性功能障碍和社交恐惧症；头痛；偏头痛；和胃肠道疾病。
• Ethynylindole compounds
  申请人：ONO Pharmaceuticals, Co., Ltd.

  公开号：US08115014B2

  公开（公告）日：2012-02-14

  As a compound having a potent oral activity and a long-lasting cysLT1/cysLT2 receptor antagonistic activity, the compound of the formula (I): which exhibits potent antagonistic activity against the cysLT1/cysLT2 receptor, and have long-lasting effects even in case of oral administration, and therefore is useful as an oral agent for preventing and/or treating a variety of diseases, for example, respiratory disease (for example, asthma (bronchial asthma, etc.), chronic obstructive pulmonary disease (COPD), pulmonary emphysema, chronic bronchitis, pneumonia (interstitial pneumonia, etc.), severe acute respiratory syndrome (SARS), acute respiratory distress syndrome (ARDS), apnea syndrome, allergic rhinitis, sinusitis (acute sinusitis, chronic sinusitis, etc.), pulmonary fibrosis, coughing (chronic coughing, etc.), and the like) was developed.

  作为一种具有强效口服活性和长效cysLT1 / cysLT2受体拮抗活性的化合物，公式（I）的化合物表现出对cysLT1 / cysLT2受体的强效拮抗活性，并且即使口服也具有长效作用，因此可用作口服药物，用于预防和/或治疗各种疾病，例如呼吸系统疾病（例如哮喘（支气管哮喘等），慢性阻塞性肺疾病（COPD），肺气肿，慢性支气管炎，肺炎（间质性肺炎等），严重急性呼吸综合征（SARS），急性呼吸窘迫综合征（ARDS），呼吸暂停综合征，过敏性鼻炎，鼻窦炎（急性鼻窦炎，慢性鼻窦炎等），肺纤维化，咳嗽（慢性咳嗽等）等。
• Bicyclic heterocycles as HIV integrase inhibitors
  申请人：Naidu Narasimhulu B.

  公开号：US20060199956A1

  公开（公告）日：2006-09-07

  The invention encompasses a series cyclic bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

  该发明涵盖了一系列公式I的环状双环嘧啶酮化合物，这些化合物抑制HIV整合酶并防止病毒整合到人类DNA中。这种作用使得这些化合物可用于治疗HIV感染和艾滋病。该发明还涵盖了治疗HIV感染者的药物组合物和方法。
• N-[4-Fluorophenyl)methyl]-4,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide as an HIV integrase inhibitor
  申请人：Bristol-Myers Squibb Company

  公开号：US07491819B1

  公开（公告）日：2009-02-17

  The invention encompasses a series of bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

  该发明涉及一系列双环嘧啶酮化合物（公式I），它们能够抑制HIV整合酶并防止病毒整合到人类DNA中。这种作用使得这些化合物对治疗HIV感染和艾滋病非常有用。该发明还涉及制药组合物和治疗HIV感染者的方法。
• J. Med. Chem. 2015, 58, 6093-6113
  作者：

  DOI：——

  日期：——